KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $2.3 billion.

  • West Pharmaceutical Services' Non-Current Assets rose 885.86% to $2.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $9.0 billion, marking a year-over-year increase of 1057.38%. This contributed to the annual value of $2.3 billion for FY2025, which is 885.86% up from last year.
  • According to the latest figures from Q4 2025, West Pharmaceutical Services' Non-Current Assets is $2.3 billion, which was up 885.86% from $2.3 billion recorded in Q3 2025.
  • West Pharmaceutical Services' 5-year Non-Current Assets high stood at $2.3 billion for Q4 2025, and its period low was $1.4 billion during Q1 2021.
  • In the last 5 years, West Pharmaceutical Services' Non-Current Assets had a median value of $1.8 billion in 2023 and averaged $1.8 billion.
  • Per our database at Business Quant, West Pharmaceutical Services' Non-Current Assets surged by 251.89% in 2022 and then soared by 1919.32% in 2024.
  • West Pharmaceutical Services' Non-Current Assets (Quarter) stood at $1.6 billion in 2021, then increased by 7.98% to $1.7 billion in 2022, then rose by 11.54% to $1.9 billion in 2023, then rose by 11.21% to $2.1 billion in 2024, then increased by 8.86% to $2.3 billion in 2025.
  • Its Non-Current Assets stands at $2.3 billion for Q4 2025, versus $2.3 billion for Q3 2025 and $2.3 billion for Q2 2025.